01
Cash & equivalents decreased 43.4%
Cash & equivalents changed -43.4% from the comparable as-filed period.
$190.6M→$107.9MComparable → current
· Biological Products, (No Diagnostic Substances)
RESEARCH SNAPSHOTVor Biopharma Inc.'s latest supported as-filed period reports net income of -$62.8M, 96.0% above the comparable as-filed period. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed -43.4% from the comparable as-filed period.
Net income changed +96.0% from the comparable as-filed period.
Operating income changed +82.6% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
VOR · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001193125-26-343607SEC ↗4Jul 21, 2026Period Jul 16, 20260001231919-26-000776SEC ↗4Jul 9, 2026Period Jul 7, 20260001193125-26-299665SEC ↗8-KJul 7, 2026Period Jul 6, 20260001193125-26-297454SEC ↗4Jun 12, 2026Period Jun 11, 20260001231919-26-000633SEC ↗4Jun 12, 2026Period Jun 11, 20260001193125-26-270002SEC ↗4Jun 12, 2026Period Jun 11, 20260001193125-26-270000SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Jul 16, 2026Filed Jul 21, 2026 | RA CAPITAL MANAGEMENT, L.P.Reporting owner | OtherIndirect | 2,100,000 | $0 | $4,200 | Form 4 ↗ |
| Jul 16, 2026Filed Jul 21, 2026 | RA CAPITAL MANAGEMENT, L.P.Reporting owner | Open Market SaleIndirect | 213 | $20 | $4,207 | Form 4 ↗ |
| Jul 16, 2026Filed Jul 21, 2026 | RA CAPITAL MANAGEMENT, L.P.Reporting owner | OtherIndirect | 2,100,000 | $5 | $10.5M | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Research & development changed -90.1% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Stock-based compensation changed +409.7% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001193125-26-269999